Metastatic Adenocarcinoma of the Pancreas
Conditions
Keywords
Metastatic Adenocarcinoma of the Pancreas
Brief summary
The purpose of this study is to determine efficacy of the treatment with erlotinib in combination with capecitabine in patients with advanced pancreatic cancer.
Detailed description
This efficacy will be determined by objective response rate following RECIST criteria.
Interventions
DRUGcapecitabine + erlotinib
6 cycles (3 weeks each one) of : * capecitabine 1000mg/m2, bid, oral. Days: 1-14 every three weeks * erlotinib (Tarceva®) 150mg/day, oral. Days: every days
Sponsors
Grupo Gallego de Investigaciones Oncologicas
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Ability to understand and willingness to sign a written informed consent 2. Informed consent signed by the patient 3. Age \> 18 years old 4. Able to fulfill all criteria from the protocol 5. Performance status Karnofsky ≥ 60% (ECOG 0-2) 6. Life expectancy ≥ 12 weeks 7. Histologically or cytological (excluding endocrine pancreatic tumour), with metastatic (stage IV), following 6th edition of TNM classification 8. Measurable disease following RECIST criteria 9. Adequate bone marrow function as determined by: * Absolute Neutrophil account (ANC) ≥ 1,5 x 109/L * Platelets: ≥ 100 x 109/L * Hemoglobin: ≥ 9 g/dL. 10. Adequate liver function, as determined by: * Serum bilirubin (total): ≤ 1,5 x LSN * AST, ALT ≤ 2,5 x LSN in patients without liver metastasis. In patients with liver metastasis ≤ 5 x LSN 11. Adequate renal function, as determined by: * Clearance creatinine \> 60.0 ml/min 12. Men or women potentially fertile (including postmenopausal women amenorrheic at least 24 months before the study) should use adequate contraceptive methods (oral contraceptives, intrauterine disposal, barrier methods together with spermicide or surgery sterilization)
Exclusion criteria
1. Local pancreatic cancer (stage IA-IIB) or locally advance cancer (stage III), following the TNM 6th edition classification. Patients with metastatic disease that relapse after the initial diagnosis of local or advance disease could be included in this study. 2. Evidence of medullary compression, carcinomatosis meningitis or brain metastasis. In case of clinical suspicious of brain metastasis is mandatory to perform a brain TAC/MR 4 weeks prior inclusion. 3. Previous systemic treatment for metastasis pancreas cancer. Adjuvant chemotherapy is permitted ≥ 4 weeks prior de inclusion. All toxicities from the adjuvant treatment must been solve before the inclusion and should be confirmed the diseases progression (metastatic disease) alter adjuvant treatment 4. Primary tumours Developer 5 years previous to the inclusion, except in situ cérvix carcinoma or skin basocellular cancer properly treated 5. Non-controlled hypertension or cardiovascular disease clinically significant (active): * Cerebrovascular accident/ictus (≤ 6 weeks prior to inclusion) * Heart attack (≤ 6 months prior to inclusion) * Instable angina * Congestive cardiac insufficiency (grade II or superior following to New York Heart Association (NYHA) * Severe cardiac arrhythmia that require medication 6. Significant ophthalmology anomalies 7. Deficit in dihydropyrimidine dehydrogenase (DPD) 8. Unable to take oral drug. Previous surgical process that affect the absorption or make the needed to have intravenous feeding or parenteral nutrition with lipids. 9. Pregnancy women or in latency period. Negative pregnancy test needed 7 days prior to initiation drug study 10. Actual or 30 days previous to study treatment with other investigational drug or participation in other trial 11. Previous treatment with Capecitabine or EGFR inhibitor. 12. Any other disease, metabolic disease 13. Known hypersensibility to any study drug or any of their component, or to 5-fluorouracile
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective response rate following RECIST criteria | within study period |
Secondary
| Measure | Time frame |
|---|---|
| 6 months survival rate | within first 6 months after study inclusion |
| Progression Free Survival (PFS) | Time from study inclusion to disease progression |
| Overall survival | within study period |
| To determine the index of clinical benefit | at the end of the study |
| To determine the safety and tolerability of erlotinib and capecitabine when administered together | Within study period |
| Time to treatment failure (TTF) | Time from study inclusion to treatment failure |
Countries
Spain
Outcome results
None listed